Founded in 1923 and headquartered in Denmark, Novo Nordisk is a global healthcare leader specializing in diabetes, obesity, and other chronic metabolic diseases. Built on a century of insulin innovation, the company has recently achieved historic growth through its breakthrough GLP-1 therapies, including Ozempic and Wegovy. As one of Europe’s most valuable companies by market capitalization, it operates in over 190 countries, focusing on expanding its portfolio into cardiovascular, kidney, and liver health to address the world’s most pressing chronic health challenges.
Here are some articles to give you a basic understanding of the company:
Novo Nodisk – background and history
Below is a list of articles for the company:
-
Novo Nordisk – FY25 results
Novo Nordisk 2025 Annual Report Summary Strategic Transformation and Organizational Adjustment 2025 marked a period of profound transformation for Novo Nordisk. In response to unprecedented demand in the obesity treatment market, the company refocused its strategic priorities on obesity, diabetes and their related complications, as well as rare diseases including rare blood and endocrine disorders.…
-
Novo Nordisk – History and Competitions
Novo Nordisk has evolved through four major stages, transforming from two rival Danish laboratories into a global leader in metabolic health. 1. The Rivalry Era (1923–1988) The company’s roots lie in the discovery of insulin and a long-standing competition between two entities. 2. The Merger and Consolidation (1989–1999) To compete on a global scale, the…